Eribulin (mesylate) (purity>99%, single impurity ≤ 0.15%)

Eribulin (B1939; E7389; ER-086526) mesylate (purity>99%, single impurity ≤ 0.15%) is an inhibitor for microtubule. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) inhibits the proliferation of cancer cell LM8 and Dunn, inhibits the cell migration of LM8, arrests the cell cycle at G2/M phase, and induces apoptosis in LM8. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) exhibits antitumor efficacy in mouse model^[1]. In Vitro:Eribulin mesylate (1-100 nM; 72 h) (purity>99%, single impurity ≤ 0.15%) inhibits cells proliferation, with IC₅₀s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively^[1].
Eribulin mesylate (10-50 nM; 12-72 h) (purity>99%, single impurity ≤ 0.15%) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells^[1].
Eribulin mesylate (10-50 nM; 12-72 h) (purity>99%, single impurity ≤ 0.15%) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells^[1].
Eribulin mesylate (1-50 nM; 12 h) (purity>99%, single impurity ≤ 0.15%) does not induce senescence in LM8 cells^[1].
Eribulin mesylate (1-10 nM; 16 h) (purity>99%, single impurity ≤ 0.15%) induces morphological change and suppresses cell migration in a low concentration in LM8 cells^[1]. In Vivo:Eribulin mesylate (1 mg/kg; i.v. once a week for 2 weeks) (purity>99%, single impurity ≤ 0.15%) reduces primary tumor growth and lung metastasis of osteosarcoma in mice^[1].
Eribulin mesylate (1 mg/kg; once i.v.) (purity>99%, single impurity ≤ 0.15%) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase^[1].